Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Mechanisms of Bladder Cancer Progression

Funder: National Cancer Institute

Funding period
USD 2.4 M
Funding amount
DESCRIPTION (provided by applicant): Due to tumor heterogeneity in progression and frequent recurrence, the management of bladder cancer (BCa) patients is both challenging and costly. Hyaluronic acid (HA) is a glycosaminoglycan and HYAL1 is a tumor cell-derived hyaluronidase (HAase) that degrades HA into angiogenic fragments. HYAL1, HA and HA-synthase (HAS) are molecular determinants of BCa growth, invasion and angiogenesis, and are also accurate markers of BCa diagnosis. The objectives of this proposal are to examine the mechanism by which HA-HYAL1 system promotes BCa growth and progression, how HYAL1 gene expression is regulated in BCa, and do HA-HYAL1 family of markers have any prognostic potential for BCa patients. Sulfated HA compounds inhibit HYAL1 activity and inhibit BCa growth by causing cell cycle arrest and apoptosis. 4-methylumbelliferone (4-MU) inhibits HA synthesis and inhibits BCa cell growth by inducing apoptosis. 4-MU and sHA are non-toxic and orally bioavailable. To examine how HYAL1 and HA regulate BCa growth and progression, we will evaluate the effects of sHA compounds and 4-MU in vitro and in an orthotopic BCa model that metastasizes to lung. The intracellular mechanisms by which sHA and 4-MU induce cell cycle arrest and/or apoptosis and affect HA receptor-mediated signaling in BCa and normal cells will also be examined (Aim 1). Currently, it is unknown how HYAL1 expression is regulated in normal and tumor tissues. Cloning of HYAL1 promoter showed that DNA methylation and certain transcription factors are involved in HYAL1 gene regulation in BCa cells. To examine the mechanism of HYAL1 regulation, a promoter methylation and HYAL1 expression will be evaluated in a cohort of normal and BCa tissues. Interaction between a transcription factor and HYAL1 promoter will be evaluated in BCa cells and tissues by EMSA and ChiP assay and siRNA transfection. Regulation of methylation and HYAL1 promoter activity by HA-HYAL1 signaling will also be evaluated (Aim 2). In BCa, the expression of HA, HYAL1 and HA-syntheses (HAS1, 2, 3) is elevated. The efficacy of HA-HYAL1 family of markers to predict disease progression, tumor recurrence and treatment response will be evaluated in a multi-center retro-prospective study that involves tissue microarrays (Aim 3). This study should reveal how HA-HYAL1 promotes BCa growth and progression and whether it can be controlled by HA and HAase inhibitors. It will also reveal how HYAL1 expression is regulated in BCa tissues and may suggest ways to control it. The study should establish whether HA- HYAL1 family members can predict prognosis for BCa patients.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting TAM (Tyro3-Axl-Mer) family of transmembrane receptor tyrosine kinases in bladder cancer.

Bladder Cancer Advocacy Network to Arpita Roy

USD 1,700
2018 - 2018
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 902,622
2018 - 2023
Project list item
Subtyping Bladder Cancer: A Multi-omic, Exposure-informed, Genealogical Approach (MErGE)

National Cancer Institute to HEIDI ANNE HANSON

USD 298,810
2018 - 2023
Project list item
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Canadian Institutes of Health Research to Murray Dale Krahn, Girish Satish Kulkarni, William Wai Lun Wong, George Andrew Tomlinson, Nathan Perlis, Wassim Kassouf, Peter Colin Black, Shabbir Muhammad Husayn Alibhai

USD 77,161
2018 - 2019



    0604 Genetics


    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC

    Clinical Research

  • RCDC


  • RCDC

    Urologic Diseases




    2.1 Biological and endogenous factors

  • Health Research Areas


  • Broad Research Areas

    Basic Science